However, previous studies showed ICI monotherapy has no survival benefit than docetaxel in the treatment of TKI resistant NSCLC patients (6), which may be associated with low rates of concurrent PD-L1 expression and CD8(+) TILs within the tumor microenvironment (15). This evidence concerns the gene CD8A and non-small cell lung carcinoma.